Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765248 | 0.89 | LMNA (0.36) | CA1CA2CA9 | |
| SCHEMBL1156129 | 0.84 | CA1 (0.42) | CA1CA2CA9 | |
| SCHEMBL5198921 | 0.76 | — | — | |
| SCHEMBL3754562 | 0.73 | CYP2C9 (0.36) | CA1CA2CA9 | |
| SCHEMBL61667 | 0.70 | CA1 (0.47) | CA1CA2CA9 | |
| SCHEMBL5198975 | 0.69 | — | — | |
| SCHEMBL1450521 | 0.68 | CA2 (0.33) | CA2 | |
| SCHEMBL2332273 | 0.68 | MTNR1A (0.31) | — | |
| SCHEMBL1449809 | 0.66 | SYK (0.30) | — | |
| SCHEMBL17113561 | 0.65 | JAK2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2912037-B1 | 2-AMINOPYRIDINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | claimed |
| US-9834541-B2 | 2-aminopyridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-12-05 | — | — | US | claimed |
| US-20150353548-A1 | 2-AMINOPYRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-12-10 | — | — | US | claimed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | claimed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | claimed |
| CN-117794924-A | Compounds useful as inhibitors of ATR kinase | 苏州爱科百发生物医药技术有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023131868-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-07-13 | — | — | WO | disclosed |
| EP-2912037-B1 | 2-AMINOPYRIDINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-9834541-B2 | 2-aminopyridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170204092-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-07-20 | — | — | US | disclosed |
| EP-3172205-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016012958-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-01-28 | — | — | WO | disclosed |
| US-20150353548-A1 | 2-AMINOPYRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-12-10 | — | — | US | disclosed |
| WO-2015101928-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-09 | — | — | WO | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | CA1 3477/4885CA2 1640/4885CA9 3088/4885 |
| US-20150353548-A1 | 2-AMINOPYRIDINE COMPOUNDS | SKP2, CDKN1A, MKI67 | CA1 4786/4885CA2 2683/4885CA9 4012/4885 |
| US-20170204092-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | NAMPT, NNT, NAPRT | CA1 3275/4885CA2 2157/4885CA9 3536/4885 |
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | CA1 1466/4885CA2 236/4885CA9 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.